// App-Quantinova.ai

: Pomalidomide + Bortezomib + Low-Dose Dexamethasone Vs Bortezomib + Low-Dose Dexamethasone As Second-Line Treatment in Patients with Lenalidomide-Pretreated Multiple Myeloma: A Subgroup Analysis of the Phase 3 Optimismm Trial

Researchers

Presenter

  • Meletios A Dimopoulos

Principal Investigators

  • Philippe Moreau

  • Larry Anderson

  • Darrell J White

  • Jesus F San-Miguel

  • Pieter Sonneveld

  • Monika Engelhardt

  • Matthew W Jenner

  • Alessandro Corso

  • Jan Drig

  • Michel Pavic

  • Morten Salomo

  • Xin Yu

  • Tuong Vi Nguyen

  • Amine Bensmaine

  • Teresa Peluso

  • Mohamed Zaki

  • Paul Richardson

Medical Centers

  • National and Kapodistrian University of Athens, Athens, Greece

  • Department of Hematology, Oncology and Immunology, University Hospital Tuebingen, Tuebingen, Germany

  • University Hospital Hotel-Dieu, Nantes, France

  • UTSouthwestern Medical Center, Dallas, TX

  • Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada

  • Clinica Universidad de Navarra, Pamplona, Spain

  • Department of Hematology, Erasmus MC Cancer Insitute, Rotterdam, Netherlands

  • Universitatsklinikum Freiburg, Freiburg, Germany

  • Southampton General Hospital, Southampton, United Kingdom

  • Policlinico San Matteo Universita Di Pavia,Pavia,Italy

  • University Hospital of Essen, Essen, Germany

  • Centre Hospitalier Universitaire De Sherbrooke (CHUS) - Centre de Recherche Clinique Etienne-Le Bel (CRCELB) Hopital Fleurimont,Sherbrooke,Canada

  • Copenhagen Univ Hosp Rigshospitalet, Kobenhavn O, Denmark

  • Celgene Corporation, Summit, NJ

  • Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA

Locations

  • Greece

  • Germany

  • France

  • United States

  • Canada

  • Spain

  • Netherlands

  • United Kingdom

  • Italy

  • Denmark

Companies

  • Celgene Corporation

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • Lenalidomide

  • Bortezomib

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved